STAT Plus: Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit
And so, another working week will soon draw to a close. Not a moment, too soon, yes? This is, you may recall, our treasured signal for daydreaming about weekend plans. Under the circumstances, you may not be surprised to hear our agenda is quite modest. We plan to catch up on our reading, take a constitutional or two, and train the official mascot to do household chores. And what about you? This is a fine time to do some spring cleaning. Conversely, you could partake in the great outdoors (but try to avoid crowds). Or perhaps reach out to folks who feel isolated. Well, whatever you do, have a grand time. But be safe, and wear a mask. Enjoy, and see you soon. …
The Trump administration mishandled the initial distribution of remedesivir, the experimental Gilead Sciences (GILD) Covid-19 medicine, delaying treatment to some critically ill patients, The Washington Post reports. The first tranche of 607,000 vials was distributed in early May — in some cases to the wrong hospitals, to hospitals with no intensive care units and therefore no eligible patients, and to facilities without needed refrigeration for storage, meaning some had to be returned to the government.
Continue to STAT Plus to read the full story…
